HK Stock Market Move | CANSINOBIO(06185) rose by more than 6% after the DTcP-Hib-MCV4 combined vaccine received approval for clinical trials.

CANSINOBIO (06185) rose more than 6%, as of the time of publication, it was up 6.41% to HK$36.5, with a trading volume of HK$30.3748 million. On the news front, CANSINOBIO announced that its adsorbed non-cellular pertussis component (DTcP) bivalent Haemophilus influenzae type b (Hib) and serogroup ACYW135 meningococcal conjugate vaccine (DTcPHib-MCV4 conjugate vaccine) has been approved by the China National Medical Products Administration for conducting related clinical trials. The company pointed out that its domestically developed quadrivalent meningococcal conjugate vaccine, Menhibrix, is currently a component of the DTcP-Hib-MCV4 conjugate vaccine and has obtained a drug registration certificate and commercialization. The DTcP for infants is in the phase III clinical stage, while the Hib vaccine is in the phase I clinical stage.